



Wiede, F., Brodnicki, T. C., Goh, P. K., Leong, Y. A., Jones, G. W., Yu, D., Baxter, A. G., Jones, S. A., Kay, T. W. H., & Tiganis, T. (2019). T Cell-Specific PTPN2-Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Co-Morbidities. *Diabetes*, 68(6), 1251-1266. <https://doi.org/10.2337/db18-1362>

Peer reviewed version

License (if available):  
Other

Link to published version (if available):  
[10.2337/db18-1362](https://doi.org/10.2337/db18-1362)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via American Diabetes Association at <https://doi.org/10.2337/db18-1362> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>



**T cell-specific PTPN2-deficiency in NOD mice accelerates the development of type 1 diabetes and autoimmune co-morbidities**

Journal:	<i>Diabetes</i>
Manuscript ID	DB18-1362.R1
Manuscript Type:	Original Article: Immunology and Transplantation
Date Submitted by the Author:	06-Mar-2019
Complete List of Authors:	Wiede, Florian; Monash University Brodnicki, Thomas; St Vincent's Institute, Immunology & Diabetes Goh, Pei; Monash University Leong, Yew; Monash University Jones, Gareth; Cardiff University Yu, Di; Monash University Baxter, Alan; James Cook University, Comparative Genomics Centre Jones, Simon; Cardiff University Kay, Thomas; St. Vincent's Institute, Immunology and Diabetes Tiganis, Tony; Monash University, Biochemistry and Molecular Biology

SCHOLARONE™  
Manuscripts

**T cell-specific PTPN2-deficiency in NOD mice accelerates the development of type 1 diabetes and autoimmune co-morbidities.**

Florian Wiede <sup>1, 2, 3 \*</sup>, Tom Brodnicki <sup>4, 5</sup>, Pei Kee Goh <sup>1, 2, 3</sup>, Yew A. Leong <sup>2</sup>, Gareth W. Jones <sup>6, 7, 8</sup>, Di Yu <sup>2</sup>, Alan G. Baxter <sup>9</sup>, Simon A. Jones <sup>6, 7</sup>, Tom Kay <sup>4, 5</sup> and Tony Tiganis <sup>1, 2, 3\*</sup>

<sup>1</sup>Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia, <sup>2</sup>Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, <sup>3</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia, <sup>4</sup> St. Vincent's Institute, Fitzroy, Victoria 3065, Australia, <sup>5</sup> Department of Medicine, St. Vincent's Hospital, The University of Melbourne, Fitzroy, Victoria 3065, Australia, <sup>6</sup>Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK, <sup>7</sup>Systems Immunity University Research Institute, Cardiff University, Cardiff, Wales, UK, <sup>8</sup>School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK, <sup>9</sup>Comparative Genomics Centre, James Cook University, Townsville, QLD, Australia.

\* Co-corresponding authors:

Tony Tiganis

Phone: +61 3 9902 9332

Email: [Tony.Tiganis@monash.edu](mailto:Tony.Tiganis@monash.edu)

[Tony.Tiganis@petermac.org](mailto:Tony.Tiganis@petermac.org)

Florian Wiede

Phone: +61 3 85595967

Email: [Florian.Wiede@petermac.org](mailto:Florian.Wiede@petermac.org)

## SUMMARY

Genome-wide association studies have identified *PTPN2* as an important non-major histocompatibility complex gene for autoimmunity. Single nucleotide polymorphisms that reduce *PTPN2* expression have been linked with the development of varied autoimmune disorders, including type 1 diabetes. The tyrosine-phosphatase PTPN2 attenuates T cell receptor and cytokine signalling in T cells to maintain peripheral tolerance, but the extent to which PTPN2-deficiency in T cells might influence type 1 diabetes onset remains unclear. Non-Obese Diabetic (NOD) mice develop spontaneous autoimmune type 1 diabetes, similar to that seen in humans. T cell PTPN2-deficiency in NOD mice markedly accelerated the onset and increased the incidence of type 1 diabetes, as well as that of other disorders, including colitis and Sjogren's syndrome. Although PTPN2-deficiency in CD8<sup>+</sup> T cells alone was able to drive the destruction of pancreatic  $\beta$  cells and onset of diabetes, T cell-specific PTPN2-deficiency was also accompanied by increased CD4<sup>+</sup> T-helper type 1 differentiation and T follicular helper cell polarisation and an increased abundance of B cells in pancreatic islets as seen in human type 1 diabetes. These findings causally link PTPN2-deficiency in T cells with the development of type 1 diabetes and associated autoimmune co-morbidities.

## INTRODUCTION

Autoimmune diseases encompass a broad range of heterogeneous and complex disorders. They include systemic disorders such as Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis, and organ-specific diseases such as Graves' disease, Hashimoto's thyroiditis, Crohn's disease and type 1 diabetes mellitus (1). Although considerable progress has been made in understanding the cellular basis of immune tolerance and the development of autoimmunity, the molecular mechanisms that underpin most autoimmune disorders remain incompletely understood. Most autoimmune diseases are associated with specific alleles of the major histocompatibility complex (MHC) locus, but genome-wide associations studies (GWAS) have identified more than 200 non-MHC loci for which alleles are associated with one or more autoimmune diseases (1). Most polymorphisms identified by GWAS are non-coding variants that are predicted to modulate gene expression, with several implicated in functional pathways that influence T- and B-cell activation (1).

GWAS have identified *PTPN2*, encoding protein tyrosine phosphatase (PTP) non-receptor type 2 (PTPN2), also known as T cell PTP, as an important non-MHC locus gene for autoimmunity (2-8). Non-coding *PTPN2* single nucleotide polymorphisms (SNPs) have been associated with autoimmune disorders including Crohn's disease, rheumatoid arthritis and type 1 diabetes (2-8). For example, the type 1 diabetes-associated *PTPN2* SNP rs1893217 has been linked with a 40% decrease in *PTPN2* expression in CD4<sup>+</sup>CD25<sup>+</sup> T<sub>reg</sub> and CD4<sup>+</sup>CD45RO<sup>+</sup> memory T cells (9). More recently, coding region *PTPN2* variants that affect mRNA stability or alter protein structure have been associated with early onset type 1 diabetes (10), whereas non-coding *PTPN2* SNPs linked with Crohn's disease, ulcerative colitis, rheumatoid arthritis and type 1 diabetes, have been reported to decrease *PTPN2* in colonic lamina

propria fibroblasts from patients with Crohn's disease (11; 12). Thus, *PTPN2* SNPs resulting in decreased *PTPN2* expression might determine the course of autoimmunity through influencing both immune and non-immune cell populations.

Studies in mice lacking *PTPN2* have identified critical roles for this regulatory enzyme in T-cell driven immunity, inflammation and metabolism (13; 14). Changes in these processes are also frequently seen in autoimmune and inflammatory diseases where *PTPN2* polymorphisms are associated with disruption of T cell tolerance (15). *PTPN2* dephosphorylates and inactivates the SRC family kinases (SFKs) LCK and FYN to 'tune' T cell receptor (TCR) signalling (15-17) and influence thymocyte development and peripheral T cell responses in the periphery to low affinity self-antigens to prevent inappropriate T cell activation (15; 18; 19). In addition, *PTPN2* dephosphorylates and inactivates Janus-activated kinases (JAKs)-1 and -3 (20) and signal transducers and activators of transcription (STATs)-1, -3 and -5 to influence T cell responsiveness to various cytokines, including interferon (IFN)- $\gamma$  and interleukins (IL)-2, -6, -7, -15, and -21 (15; 17-19; 21). Beyond its role in T cells, *PTPN2* might affect the activation of innate and adaptive immune cells, including B cells, dendritic cells and myeloid cells (20; 22; 23) as well as stromal cells (24) to influence disease progression. Consistent with this, *Ptpn2*<sup>-/-</sup> mice that develop wasting disease succumb within weeks of birth (13; 14). Similarly, the inducible deletion of *PTPN2* in the hematopoietic compartment of adult C57BL/6 mice (*Mx1-Cre;Ptpn2*<sup>fl/fl</sup>) promotes systemic inflammation and overt autoimmunity within 4 weeks of *PTPN2* deletion, with mice exhibiting dermatitis, glomerulonephritis, pancreatitis and overt liver disease (22). Beyond the effector/memory T cell phenotype, hematopoietic *PTPN2*-deficiency resulted in the accumulation of inflammatory monocytes and B cells and germinal centre formation linked with increased T follicular helper (T<sub>FH</sub>) cells, germinal centre

B cells and IgG-secreting B cells (22). Therefore, PTPN2 deficiency might not only impact on T cell function, but also drive the pathogenic accumulation of T<sub>FH</sub> cells and high-affinity antigen-specific IgG secreting B cells to promote autoimmunity.

Mice lacking PTPN2 in the hematopoietic compartment develop insulinitis (infiltration of lymphocytes in pancreatic islets of Langerhans) (22) reminiscent of in early stage disease in humans with type 1 diabetes. However, this phenotype does not result in type 1 diabetes in C57BL/6 mice, even when PTPN2 is additionally deleted in pancreatic  $\beta$  cells (22). Similarly, these mice do not develop inflammatory bowel disease or inflammatory arthritis (22); diseases that are often associated with *PTPN2* loss of function SNPs (3; 5-8). Therefore, although deficiencies in T cells or the hematopoietic system may result in a loss of tolerance and the development of autoimmunity in C57BL/6 mice, the extent to which PTPN2 deficiency in T cells and/or other immune cells contributes to the onset, maintenance and severity of human autoimmunity remains unclear.

To explore the influence of PTPN2-deficiency in T cells on autoimmunity, especially type 1 diabetes, we backcrossed the *Lck-Cre* and *Ptpn2<sup>fl/fl</sup>* loci, originally generated in C57BL/6 mice, onto the Non-Obese Diabetic (NOD) background. Unlike other mouse models, NOD mice develop spontaneous autoimmune type 1 diabetes, similar to that seen in humans, sharing many of the diabetes susceptibility loci and autoantigens that contribute to the development of type 1 diabetes (25). PTPN2 deficiency in T cells in NOD mice markedly accelerated the onset and increased the cumulative incidence of type 1 diabetes. The development of inflammatory/autoimmune co-morbidities was also accelerated. Disease progression was associated with the infiltration of cytotoxic CD8<sup>+</sup> T cells, along with CD4<sup>+</sup> T-helper type 1 (T<sub>H1</sub>) and T<sub>FH</sub> polarisation, as detected in human type 1 diabetes (26).

These findings suggest that PTPN2-deficiency in T cells might be sufficient to promote the development of type 1 diabetes and autoimmunity in genetically susceptible individuals.



## METHODS

### *Mice*

*Lck-Cre;Ptpn2<sup>fl/fl</sup>*.C57BL/6J mice (15) were backcrossed onto the NOD/Lt background for 11 generations. A genome-wide screen was performed by the Australian Genome Research Facility using the iPLEX GOLD chemistry and the Sequenom MassArray spectrometer for SNP genotyping. Data was analyzed using the GeneChip Targeted Genotyping System Software. *Lck-Cre;Ptpn2<sup>fl/fl</sup>*;NOD and *Ptpn2<sup>fl/fl</sup>*;NOD littermate mice were maintained on a 12 h light-dark cycle in a temperature-controlled specific-pathogen-free high barrier facility (ARL, Monash University) with free access to food and water. Aged- and sex-matched littermates were fed a standard chow diet (8.5% fat; Barastic, Ridley, AgriProducts, Australia).

### *Materials*

Recombinant mouse IL-2, IL-6, IL-12, IFN- $\gamma$  and TGF $\beta$  were purchased from Peprotech. Hamster  $\alpha$ -mouse CD3 $\epsilon$  (145-2C11) and hamster  $\alpha$ -mouse CD28 (37.51) were purchased from BD Biosciences. Mouse  $\alpha$ -tubulin (Ab-5) and mouse  $\alpha$ -GAPDH were purchased from Sigma-Aldrich. Rabbit  $\alpha$ -phospho-Stat1 (Tyr701, clone 58D6) and polyclonal rabbit  $\alpha$ -Stat1 were purchased from Cell Signalling. Polyclonal rabbit  $\alpha$ -phospho-Stat4 (Tyr693) was from Thermo Fisher Scientific.

Percoll was purchased from GE Healthcare and Dnase I from Sigma-Aldrich. Complete T cell medium [RPMI-1640 supplemented with 10% (v/v) FBS, L-glutamine (2 mM), penicilin (100 units/ml)/streptomycin (100  $\mu$ g/ml), non-essential amino acids, Na-pyruvate (1 mM), HEPES (10 mM) and 2- mercaptoethanol (50  $\mu$ M)] was purchased from Thermo Fisher Scientific. Dulbecco-Phosphate Buffered Saline (D-

PBS), Dulbecco's Modified Eagle's Medium (DMEM) and Hank's Buffered Salt Solution (HBSS) were from Thermo Fisher Scientific and collagenase IV from Worthington.

### ***Flow cytometry***

Single cell suspensions from thymus, spleen, inguinal lymph nodes, pancreatic lymph nodes and mesenteric lymph nodes were obtained by gently pressing the tissue through a 40  $\mu$ M FALCON cell strainer (BD Biosciences). Erythrocytes were removed by incubating cells with Red Blood Cell Lysing Buffer Hybri-Max™ for 7 min at room temperature. Cells counts were determined with the Z2-Coulter Counter (Beckman Coulter). For surface staining, cells ( $1 \times 10^6/10\mu$ l) were resuspended in D-PBS supplemented with 2% (v/v) FBS and stained in 96-well microtiter plates (BD Falcon™) for 20 min on ice. Cells were washed twice and resuspended in D-PBS/2% FBS and analysed using a LSRII, Fortessa, Symphony (BD Biosciences) or Cyan™ ADP (Beckman Coulter) or purified using an Influx sorter (BD Biosciences). Data was analysed using FlowJo v8.7, v9.4 or v10.2 (Tree Star Inc.) software.

For detection of intracellular FoxP3, the Foxp3/Transcription Factor Staining Buffer set (eBioscience) was used according to the manufacturer's instructions. For the detection of intracellular cytokines, the BD Cytfix/Cytoperm™ Kit according was used to the manufacturer's instructions. Serum cytokines were quantified with the BD Cytometric Bead Array (CBA) Mouse Inflammation Kit according the to the manufacturer's instructions.

### ***Type I diabetes assessment***

Glycosuria in was determined using Diastix Reagent Strips for Urinanalysis (Bayer). Mice were scored as diabetic after two positive readings (urine glucose  $\geq 55$  mmol/l) 48 hours apart. This was confirmed by measuring blood glucose levels that were found to be greater than 18 mmol/l in each case. Pancreata were fixed in formalin and processed for histological analysis (hematoxylin and eosin: H&E) and scored for the degree of insulitis (grades 0-4). Grade 0 represents no infiltrate, grade 1 periductal accumulation of mononuclear cells, grade 2 circumferential accumulation of mononuclear cells, grade 3 intra-islet infiltration, and grade 4 severe structural derangement and complete  $\beta$  cell loss.

### ***Isolation of pancreas-infiltrating T cells***

Pancreata from 5 week old pre-diabetic *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD and *Ptpn2<sup>fl/fl</sup>*.NOD littermate mice were harvested and pancreatic lymph nodes removed. Pancreata were digested in DMEM containing 1 mg/ml collagenase IV (Worthington) at 37°C for 15 min and single cell suspensions processed for flow cytometry.

### ***Adoptive transfer into NOD mice***

CD8<sup>+</sup>CD44<sup>lo</sup>CD62L<sup>hi</sup> were purified from single cell suspension obtained from pooled splenocytes and lymph node cells from 5 week old prediabetic *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD and *Ptpn2<sup>fl/fl</sup>*.NOD littermate control mice using the naïve CD8<sup>+</sup> T cell Isolation Kit (Miltenyi Biotech) according the manufacturer's instructions with the autoMACS Separator (Miltenyi Biotech). Naïve CD8<sup>+</sup>CD44<sup>lo</sup>CD62L<sup>hi</sup> ( $1 \times 10^7$ ) were adoptively transferred into 28 day old female NOD mice and diabetes incidence monitored.

### ***Serum immunoglobulins***

Serum IgM was quantified with the mouse IgM ELISA Ready-SET-Go™ kit from eBioscience according to the manufacturer's instructions. To detect serum IgG subsets MaxiSorp ELISA plates (Nunc) were coated with goat  $\alpha$ -mouse IgG (625 ng/ml) in ELISA coating buffer overnight at 4 °C. Plates were washed five times and blocked in D-PBS supplemented with 3% (w/v) BSA for 2 h at room temperature. Serum (IgM 1:5 serial dilutions; IgG1, IgG2a, IgG2b and IgG3, 1:10 serial dilutions) was added and plates were incubated for 1 h at room temperature. Plates were washed five times and biotinylated  $\alpha$ -IgM,  $\alpha$ -IgG1,  $\alpha$ -IgG2a (to detect  $\alpha$ -IgG2c),  $\alpha$ -IgG2b or  $\alpha$ -IgG3 (1:1000) diluted in D-PBS/1% (w/v) BSA was added. Samples were incubated for 1 h at room temperature. Plates were washed five times and incubated with Streptavidin-HRP (1:10.000 in D-PBS/1% (w/v) BSA) for 30 min followed by seven washes. 3,3',5,5'-tetramethylbenzidine (TMB) was added and samples were incubated for 15 min at room temperature in the dark. Reaction was stopped with 0.5 M sulphuric acid and absorbance was read at 450 nM.

### ***Serum insulin autoantibodies (IAA)***

ELISA plates (Costar) were coated with human insulin (10  $\mu$ g/ml, Actrapid, Novo Nordisk) overnight at 4°C. Plates were blocked with PBS supplemented with 2% BSA for 2 hours at room temperature and then incubated with sera from *Ptpn2<sup>fl/fl</sup>*.NOD, *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD or C57BL/6 mice (1:10 dilution) for 2 hours at room temperature. Plates were washed four times and further incubated with biotinylated anti-mouse IgG1 (AbCam, 1:10,000 dilution) for 30 min at room temperature. After four washes, Streptavidin-HRP (BioLegend) was added and plates were incubated for 15 min at room temperature. Plates were washed five times, TMB was added and absorbance was measured at 450 nm using a Polarstar (BMG Labtech)

microplate reader. Each sample was run in duplicates, and absorbance (450 nm) of the negative control sample (C57BL/6 serum) was subtracted from absorbance of test sample to calculate the true absorbance value for each test sample.

### ***Statistical analysis***

Statistical analysis was performed using the non-parametric using 2-tailed Mann-Whitney U Test or the Student's T-test. Statistical analyses on Kaplan-Meier estimates were performed using a Log-rank (Mantel-Cox) test with one degree of freedom. For all tests  $p < 0.05$  was considered as significant.

### ***Animal ethics***

All experiments were performed in accordance with the NHMRC Australian Code of Practice for the Care and Use of Animals. All protocols were approved by the Monash University School of Biomedical Sciences Animal Ethics Committee (Ethics number: MARP/2012/124) and the UK Home Office (project licence: PB3E4EE13).

## RESULTS

### *PTPN2 deletion in T cells promotes autoimmune diabetes*

To determine the extent to which PTPN2 deficiency in T cells might contribute to the development of type 1 diabetes we introduced the *Lck-Cre* and *Ptpn2<sup>fl/fl</sup>* loci from C57BL/6 mice (15) onto the NOD/Lt (NOD) genetic background by backcrossing for 11 generations. *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD mice were thereon bred with NOD wild type mice to produce the *Ptpn2<sup>fl/+</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD offspring that were interbred. DNA from the 11<sup>th</sup> generation was genotyped for 597 single nucleotide polymorphisms (SNPs) by the Australian Genome Research Facility using iPLEX GOLD chemistry and the Sequenom MassArray spectrometer for SNP genotyping and analysed by the GeneChip Targeted Genotyping System Software. *Ptpn2<sup>fl/+</sup>*.NOD mice had a contaminating C57BL/6-derived interval between and including *rs13483413* and *rs3656892* (~2 MB) that encompasses the floxed *Ptpn2* locus on chromosome 18, whereas *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD mice had an additional contaminating C57BL/6-derived interval on chromosome 15 between and including *rs13482618* and *rs13482719* (~28 MB) that encompasses the *Lck-Cre* transgene locus. These C57BL/6 intervals are unavoidable, but previous NODx C57BL/6 outcrosses have not identified *Idd* loci within these intervals (27).

Diabetes pathogenesis in NOD mice is characterized by severe insulitis followed by the CD4<sup>+</sup> and CD8<sup>+</sup> T cell-mediated destruction of insulin-producing  $\beta$  cells in the pancreatic islets of Langerhans. Previous studies have reported that female NOD mice first develop insulitis at 5 weeks of age and diabetes at approximately 90 days after birth, with 46% of mice having diabetes by 150 days of age (28), although this can be influenced by diet and the gut microbiome (29). By contrast, male mice are significantly less susceptible, with a much lower frequency of diabetes (28). We monitored for

diabetes in female and male *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice (**Fig. 1a-b**). The onset of diabetes (urine glucose > 55 mM; blood glucose > 18 mM) was markedly accelerated in both female and male *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. Female *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice started to develop diabetes at 36 days of age with all *Ptpn2*-deficient mice succumbing by 87 days (**Fig. 1a**). Similarly, type 1 diabetes onset in male *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice occurred at 29 days with 100% of mice developing diabetes by 108 days (**Fig. 1b**). By contrast neither male nor female *Ptpn2<sup>fl/fl</sup>*.NOD littermate mice or parental NOD mice developed diabetes by 100 days of age. Histological analysis in 30-36 day old *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice prior to the development of diabetes revealed advanced invasive insulitis [combined histological grades 3 (intra-islet infiltration) and 4 (structural derangement and complete  $\beta$  cell loss)] in 91% of islets with obliterative lesions and marked immune cell infiltrates (**Fig. 1c-d**). The immune infiltrates not only contained CD3<sup>+</sup> T cells, but also B220<sup>+</sup> B cells (**Fig. 1e**), that are thought to contribute to invasive insulitis and diabetes (30; 31). By contrast, invasive insulitis was only observed in ~2% of islets from 30-36 day old *Ptpn2<sup>fl/fl</sup>*.NOD littermate controls, and islets exhibited minimal peri-insulitis (grade 1) and immune cell infiltration (grade 0; **Fig. 1c-d**). Thus PTPN2-deficiency in T cells in NOD mice markedly accelerates pancreatic islet destruction and the onset of diabetes in NOD mice.

The type 1 diabetes-associated non-coding *PTPN2* SNP rs1893217 is accompanied by a reduction in *PTPN2* mRNA in human CD4<sup>+</sup>CD45RO memory T cells (9). Similarly, the Crohn's disease-associated non-coding *PTPN2* SNP rs2542151 that is also associated with early onset type 1 diabetes (4) is accompanied by a reduction in PTPN2 protein in primary human colonic lamina propria fibroblasts (11; 12). Thus, *PTPN2* might be haploinsufficient in the pathogenesis of autoimmune disorders such

as type 1 diabetes and Crohn's disease. We have previously shown that PTPN2-heterozygosity in *Lck-Cre;Ptpn2<sup>fl/+</sup>* mice results in an approximate 50% reduction of PTPN2 protein in T cells (18). We therefore monitored for the incidence of diabetes in *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD mice (**Fig. 1a-b**). Although delayed relative to homozygous mice, the onset of diabetes was accelerated in female *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD mice when compared to their *Ptpn2<sup>fl/fl</sup>*.NOD littermate controls. Moreover, although male *Ptpn2<sup>fl/fl</sup>*.NOD control mice did not develop diabetes, even at 250 days of age, male *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD heterozygous mice began to develop diabetes by 113 days of age. **Histological analysis in 84-105 day old *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD mice revealed invasive insulitis in 50% of islets (**Fig. 1f-g**) whereas in *Ptpn2<sup>fl/fl</sup>*.NOD mice invasive insulitis was only evident in 8% of islets.** These results emphasise the importance of PTPN2 in T cell tolerance and suggest that even partial PTPN2 deficiency in T cells might be sufficient to accelerate the onset of diabetes in autoimmune-prone individuals.

#### ***Increased T helper type 1 and cytotoxic T cells in pancreata.***

T cell responses to pro-insulin occur early in the pathogenesis of type 1 diabetes in NOD mice and are required for the development of immune responses to other antigens (32). Dendritic cells and insulin-specific CD4<sup>+</sup> T cells cross-prime CD8<sup>+</sup> T cells to elicit cytotoxic responses and the destruction of  $\beta$  cells (33). We have shown previously that PTPN2-deficiency in CD8<sup>+</sup> T cells negates the need for cross-priming and drives the differentiation and activation of effector T cells and overt responses to self-antigen (15; 18; 19). C57BL/6 mice deficient for PTPN2 in T cells progressively develop an effector/memory (CD44<sup>hi</sup>CD62L<sup>lo</sup>) T cell phenotype and autoimmunity with age (15). In *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice, we noted a significant increase in



effector/memory (CD44<sup>hi</sup>CD62L<sup>lo</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the spleens and lymph nodes of 36 day old *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice prior to the development of diabetes (**Fig. 2a-b**). We also noted a significant increase in effector/memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the pancreatic draining lymph nodes of pre-diabetic *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice (**Fig. 2c**). Notably, although hardly any CD4<sup>+</sup> or CD8<sup>+</sup> T cells were in the pancreata of age-matched *Ptpn2<sup>fl/fl</sup>*.NOD littermates, the early onset diabetes in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice was preceded by the marked infiltration of CD44<sup>hi</sup>CD62L<sup>lo</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells (**Fig. 2d**). Previous studies have established that the initiation of diabetes in NOD mice is reliant on the presence of activated insulin-specific CD4<sup>+</sup> T<sub>H1</sub> cells that produce IFN $\gamma$  and allow for the licensing of antigen-specific CD8<sup>+</sup> T cells (34; 35). We found that the CD44<sup>hi</sup>CD62L<sup>lo</sup> CD4<sup>+</sup> T cells infiltrating the pancreata of *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were enriched for CD4<sup>+</sup> T<sub>H1</sub> (IFN $\gamma$ <sup>hi</sup>) cells (**Fig. 2e**). Consistent with previous studies (36) we found that PTPN2-deficient naive CD4<sup>+</sup> T cells differentiated more efficiently into T<sub>H1</sub> cells *ex vivo*, even in the absence of IL-12, consistent with this being a cell intrinsic effect (**Fig. S1a**). At least in part the enhanced T<sub>H1</sub> differentiation may be due to the promotion STAT-1 signalling, which is required for T<sub>H1</sub> commitment and differentiation (37). STAT-1 is a *bona fide* PTPN2 substrate (38) and PTPN2-deficiency was accompanied by heightened basal and IFN- $\gamma$ -induced STAT-1 Y701 phosphorylation (**Fig. S1b**). By contrast IL-12-induced STAT-4 Y693 phosphorylation in activated CD4<sup>+</sup> T cells was unaltered by PTPN2-deficiency (**Fig. S1c**). In addition to the increased presence of T<sub>H1</sub> cells we found that infiltrating CD44<sup>hi</sup>CD62L<sup>lo</sup> CD8<sup>+</sup> T cells exhibited a terminally-differentiated and antigen-experienced CD49d<sup>hi</sup>KLRG1<sup>hi</sup>CD127<sup>-</sup> effector phenotype and expressed high levels of IFN- $\gamma$ , a marker of cytotoxic CD8<sup>+</sup> T cells (**Fig. 2f**). Taken together, these results are consistent with PTPN2 deficiency increasing the activation and pathogenic conversion

of CD4<sup>+</sup> and CD8<sup>+</sup> T cells into T<sub>H1</sub> and cytotoxic CD8<sup>+</sup> T cells respectively to mediate of destruction of pancreatic  $\beta$  cells.

To explore directly whether PTPN2 deficiency in CD8<sup>+</sup> T cells might subvert T cell tolerance to promote the CD8<sup>+</sup> T cell-mediated destruction of  $\beta$  cells, we adoptively transferred CD8<sup>+</sup> naïve (CD44<sup>lo</sup>CD62L<sup>hi</sup>) T cells from pre-diabetic *Ptpn2<sup>fl/fl</sup>*.NOD versus *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice into immunoreplete NOD hosts and monitored for diabetes (**Fig. 3**). Albeit delayed, diabetes was evident by 44 days in mice receiving PTPN2 deficient T cells with 86% of mice succumbing by 172 days post-adoptive transfer (**Fig. 3a**). By contrast the onset of diabetes was not altered in control mice and diabetes was not evident until 117 days of age (**Fig. 3a**). Histological analysis at 120 days post-adoptive transfer revealed that *Lck-Cre;Ptpn2<sup>fl/fl</sup>* CD8<sup>+</sup> T cell recipients exhibited increased invasive insulitis accompanied by marked lymphocytic infiltrates in islets (**Fig. 3b-c**). These results are consistent with the accelerated onset of diabetes in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice being largely, albeit not completely, due to perturbations in peripheral CD8<sup>+</sup> T cell tolerance to self-antigens.

### ***Increased FoxP3<sup>+</sup> regulatory T cells in PTPN2-deficient mice***

CD4<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells (T<sub>reg</sub>) prevent autoimmunity by suppressing the activity of autoreactive CD8<sup>+</sup> T cells that escape negative selection in the thymus (39). SNPs in genes encoding IL-2 and the IL-2 receptor (CD25) that are required for T<sub>reg</sub> generation have been linked with various autoimmune diseases, including type 1 diabetes (2). We therefore assessed whether the accelerated onset of type 1 diabetes evident in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice might arise through the suppression of T<sub>reg</sub> development or function (**Fig. 4**). Consistent with our previous studies in C57BL/6 mice (15; 17), we found that PTPN2-deficiency in pre-diabetic 5-week old *Lck-*

Cre;*Ptpn2*<sup>fl/fl</sup>.NOD mice was accompanied by increased thymic (CD25<sup>+</sup>FoxP3<sup>+</sup> and CD25<sup>+</sup>FoxP3<sup>+</sup>) T<sub>regs</sub> (Fig. 4a). Moreover, PTPN2 deficiency was accompanied by increased proportion of total (Fig. 4b), resting (CD44<sup>hi</sup>CD62L<sup>hi</sup>) and effector (CD44<sup>hi</sup>CD62L<sup>lo</sup>) CD25<sup>+</sup>FoxP3<sup>+</sup> T<sub>regs</sub> in the pancreata and corresponding draining lymph nodes (panLN) (Fig. 4c-d) with the increase in T<sub>regs</sub> in pancreata approximating the increase in effector/memory CD4<sup>+</sup> T cells (Fig. 4e); total and effector T<sub>regs</sub> trended higher also in the spleen and inguinal lymphoid tissues (Fig. S2a). T<sub>regs</sub> expand and acquire an activated effector phenotype in response to cognate antigens in the context of infection and autoimmunity (40). PTPN2-deficiency not only increased the proportion of effector T<sub>regs</sub>, but also increased the number of resting and effector T<sub>regs</sub> in pancreata and panLNs. By contrast antigen-independent TGFβ/IL-2-induced CD25<sup>+</sup>FoxP3<sup>+</sup> T<sub>reg</sub> generation *ex vivo* was not altered by PTPN2-deficiency (Fig. S2b). These findings are consistent with PTPN2 deficiency increasing the antigen-induced expansion and differentiation of T<sub>regs</sub> *in vivo*. To determine whether PTPN2 deficiency might abrogate T<sub>reg</sub> function we isolated splenic CD25<sup>hi</sup> T<sub>regs</sub> from *Ptpn2*<sup>fl/fl</sup>.NOD versus *Lck*-Cre;*Ptpn2*<sup>fl/fl</sup>.NOD mice and assessed their capacity to repress the TCR-mediated expansion of CD25<sup>lo</sup> CD4<sup>+</sup> T cells *ex vivo* (Fig. 4f). We found that *Lck*-Cre;*Ptpn2*<sup>fl/fl</sup> T<sub>regs</sub> were just as efficient as *Ptpn2*<sup>fl/fl</sup> T<sub>regs</sub> in repressing the α-CD3ε-induced expansion of CD4<sup>+</sup> T cells. Therefore, the accelerated onset of diabetes in *Lck*-Cre;*Ptpn2*<sup>fl/fl</sup>.NOD mice cannot be attributed to diminished T<sub>reg</sub> development or function.

### ***Increased CD4<sup>+</sup> T follicular helper cells and B cells in PTPN2-deficient mice***

Our studies indicate that PTPN2 deficiency in T cells not only promotes the infiltration of cytotoxic CD8<sup>+</sup> and CD4<sup>+</sup> T cells into the pancreata of NOD mice, but

also the recruitment of B220<sup>+</sup> B cells, which promote the expansion and activation of T cells targeting  $\beta$  cell antigens (41). Therefore, another mechanism by which PTPN2 deficiency might influence disease progression in NOD mice is through effects on the B cell compartment. CD4<sup>+</sup> T<sub>FH</sub> cells are required for the promotion of B cell maturation and the production of antigen-specific antibodies (42). Previously, we reported that the inducible deletion of *Ptpn2* in the hematopoietic compartment of adult C57BL/6 mice was accompanied by the marked expansion of T<sub>FH</sub> cells *ex vivo* (22). To explore the mechanisms by which PTPN2 deficiency in T cells might result in increased B cell pancreatic infiltrates, we investigated the presence of T<sub>FH</sub> cells and germinal centre B cells in the pancreatic draining lymph nodes of 5 week old *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. T cell PTPN2 deficiency in NOD mice resulted in a striking increase in CD4<sup>+</sup>CD44<sup>hi</sup>CXCR5<sup>hi</sup>PD-1<sup>hi</sup> T<sub>FH</sub> cells in the spleens, inguinal lymph nodes and pancreatic draining lymph nodes (**Fig. 5a**). In keeping with T<sub>FH</sub> cell expansion we found that B220<sup>+</sup>GL-7<sup>hi</sup>Fas<sup>hi</sup> germinal centre B cells were also markedly increased in spleens, inguinal lymph nodes and pancreatic draining lymph nodes (**Fig. 5b**). Germinal centre B cell expansion and class switching from IgM to IgG are reliant on interactions with germinal centre T<sub>FH</sub> cells. Consistent with this we found that circulating IgM and IgG (IgG1, IgG2c, IgG2b, IgG3) were increased in pre-diabetic *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice (**Fig. 5c**). **Importantly we found that circulating insulin autoantibodies (IAA) were elevated in 5 week old *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice as well as in 12-15 week old *Lck-Cre;Ptpn2<sup>fl/+</sup>*.NOD mice (**Fig. 5d**).** These results indicate that T cell PTPN2 deficiency in NOD mice might influence disease progression, not only through effects on CD8<sup>+</sup> T cell tolerance, but also through the CD4<sup>+</sup> T<sub>FH</sub>-mediated expansion and maturation of B cells and the production of autoantibodies.

### ***Autoimmune co-morbidities in PTPN2-deficient mice***

In addition to type 1 diabetes, NOD mice spontaneously develop autoimmune co-morbidities, including sporadic lymphoid infiltrates in the thyroid gland, mimicking Hashimoto's thyroiditis (43) and sporadic lymphoid infiltrates in the salivary and lacrimal glands, resembling the human autoimmune disorder known as Sjögren's Syndrome (44). Moreover, young NOD mice can develop subclinical colitis after weaning due to defective tolerance to commensal gut bacteria (45). Such autoimmune co-morbidities are also seen in a subset of patients with type 1 diabetes (46). Previous studies have shown that PTPN2-deficiency in T cells or the haematopoietic compartment of C57BL/6 mice promotes systemic inflammation and autoimmunity accompanied by lymphocytic infiltrates in non-lymphoid tissues such as liver, lung, skin and kidney (15; 22). We therefore assessed the impact of PTPN2 deficiency on the development of systemic inflammation and autoimmunity in pre-diabetic 5-6 week old *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. PTPN2 deficiency in T cells was accompanied by systemic inflammation as reflected by the increase in circulating pro-inflammatory cytokines TNF $\alpha$  and IL-6 (**Fig. 6a**) and the infiltration of lymphocytes, including B220<sup>+</sup> B cells and CD3<sup>+</sup> T cells into the submandibular salivary glands (**Fig. 6b**). In these young pre-diabetic mice, lymphocytic infiltrates were not evident in liver, lung, kidney or joints and there was no evidence of inflammatory arthritis (**Fig. S3a-b**). Strikingly however, we found marked lymphocytic infiltrates in the colons of pre-diabetic *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice and the development of overt colitis as reflected by colon shortening (**Fig. 6c**). The development of colitis was accompanied by an increased number of CD4<sup>+</sup> and CD8<sup>+</sup> effector/memory (CD44<sup>hi</sup>CD62L<sup>lo</sup>) T cells, T<sub>FH</sub> cells (CD4<sup>+</sup>CD44<sup>hi</sup>CXCR5<sup>hi</sup>PD-1<sup>hi</sup>) and germinal centre B cells (B220<sup>+</sup>GL-7<sup>hi</sup>Fas<sup>hi</sup>) in the mesenteric lymph nodes; no alterations were evident in CD4<sup>+</sup>FoxP3<sup>+</sup> T<sub>reg</sub> cells (**Fig.**

**7a).** Moreover, colitis was accompanied by the accumulation of lamina propria CD4<sup>+</sup> and CD8<sup>+</sup> effector/memory T cells with T<sub>H1</sub> and cytotoxic phenotypes respectively (**Fig. 7b-c**), as assessed by their ability to produce IFN $\gamma$  *ex vivo* (**Fig. 7c**). No significant differences were evident in the proportion of lamina propria CD4<sup>+</sup> T<sub>H17</sub> cells (**Fig. 7c**) and T<sub>H17</sub> generation *ex vivo* was not affected by PTPN2-deficiency (**Fig. S4a**). Similarly, intraepithelial and lamina propria TCR $\gamma\delta$ <sup>+</sup> T cells in the colons of *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were not altered (**Fig. S4b**). These results are consistent with T cell PTPN2 deficiency in NOD mice driving the development of not only type 1 diabetes, but also other autoimmune/inflammatory disorders.

## DISCUSSION

Many overlapping tolerance mechanisms exist that normally prevent self-reactive B and T cells from attacking the body during homeostatic processes and antimicrobial defence. Molecules that negatively regulate T cell and B cell signalling are fundamentally important for tuning T cell and B cell responses to prevent overt autoreactivity. PTPN2 negatively regulates TCR signalling to prevent overt autoreactivity to low-affinity self-peptide-MHC complexes (15; 18; 19). Here, we demonstrate that PTPN2 deficiency in T cells alone is sufficient to markedly exacerbate disease onset and severity of diabetes in autoimmune-prone NOD mice.

The development of type 1 diabetes in NOD mice is characterised by the infiltration of antigen-specific T<sub>H1</sub>-polarised CD4<sup>+</sup> and cytotoxic CD8<sup>+</sup> T cells into pancreatic islets, resulting in the lymphocyte driven destruction of insulin-producing  $\beta$ -cells (25; 47). In this study we found that the transfer of naive PTPN2-deficient CD8<sup>+</sup> T cells alone into immunoreplete NOD hosts accelerated the onset and increased the incidence of type 1 diabetes. These findings are consistent with PTPN2-deficiency in CD8<sup>+</sup> T cells enhancing TCR-instigated responses to self to promote autoimmunity. However, as the onset of diabetes in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice exceeded that in which PTPN2-deficient CD8<sup>+</sup> T cells alone had been transferred, it is probable that perturbations in other T cell subsets might also contribute to disease progression. We have shown previously that PTPN2-deficiency enhances the TCR-induced activation and differentiation of CD4<sup>+</sup> T cells into effector/memory T cells (15; 19). Consistent with this, effector/memory CD4<sup>+</sup> T cells were increased in the pancreatic draining lymph nodes and the pancreata of *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. The recruitment and activation of CD4<sup>+</sup> T cells can contribute to the licensing and activation of CD8<sup>+</sup> T cells. However, as PTPN2-deficiency in CD8<sup>+</sup> T cells negates the need for CD4<sup>+</sup> T cell

help during antigen cross-presentation and permits the helper-independent acquisition of cytotoxic activity to self-antigens (19), we surmise that other CD4<sup>+</sup> T cell-dependent mechanisms may be more pertinent.

Spalinger *et al* (36) have reported that PTPN2 deficiency in CD4<sup>+</sup> T cells can enhance T<sub>H1</sub> polarisation, but impair T<sub>reg</sub> generation in dextran sodium sulfate or T-cell transfer colitis models. Consistent with this we also noted an overt T<sub>H1</sub> polarisation in pre-diabetic *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. Pioneering work by Katz *et al.* (35) has shown that T<sub>H1</sub> cells, but not T<sub>H2</sub> cells are required for autoimmune diabetes, whereas a large number of studies have defined the importance of T<sub>H1</sub> cell signature cytokine in promoting the development of insulinitis and type 1 diabetes in NOD mice (48). Therefore, the enhanced T<sub>H1</sub> polarisation in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice is likely to be an important contributor to the accelerated onset of type 1 diabetes. However, in contrast to the findings of Spalinger *et al.* (36) we found that thymic T<sub>regs</sub> and effector-like T<sub>regs</sub> in the pancreata and draining lymph nodes in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were increased, rather than decreased. Consistent with this, previous studies have shown that PTPN2 dephosphorylates JAK-1/3 and STAT-5 and attenuates IL-2-induced STAT-5 signalling in thymocytes to suppress the generation of FoxP3<sup>+</sup> T<sub>regs</sub> (49). Moreover we have shown previously that *Ptpn2* deletion in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.C57BL/6 mice or *Mx1-Cre;Ptpn2<sup>fl/fl</sup>*.C57BL/6 mice in which *Ptpn2* has been inducibly deleted increases the thymic generation of CD25<sup>+</sup>FoxP3<sup>+</sup> T<sub>regs</sub> and does not compromise T<sub>reg</sub> function *ex vivo* (15; 22). **In this study we reaffirmed PTPN2-deficiency does not compromise the suppressor properties of T<sub>regs</sub> isolated from NOD mice.** Therefore, defective T<sub>reg</sub> generation/function is unlikely to contribute to the loss of tolerance in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice.

An additional mechanism by which PTPN2-deficient CD4<sup>+</sup> T cells may



facilitate the development of type 1 diabetes is by promoting the role of B cells in progression towards invasive insulitis and diabetes. Although B cells are not essential for the generation or effector function of islet-reactive T cells, they can contribute to the development of autoreactivity (41). Indeed anti-CD20-mediated B cell depletion (50), or the arrest of B cell maturation by disabling IgM production (30), protects against type 1 diabetes in NOD mice, whereas CD19 deletion on NOD B cells diminishes the expansion of  $\beta$  cell antigen-specific T cells (31). In humans, B cell-depletion with anti-CD20 can delay disease progression in patients with newly diagnosed type 1 diabetes (51). In our studies we found a marked infiltration of B220<sup>+</sup> B cells into the pancreatic islets of *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. This was accompanied by a significant increase in the number of germinal centre B220<sup>+</sup> B cells in lymphoid organs, including in the draining lymph nodes of the pancreas. The increase in germinal centre B cells was in turn accompanied by the expansion of CD4<sup>+</sup> T<sub>FH</sub> cells in lymphoid organs. T<sub>FH</sub> cells are required for the formation of germinal centres, the promotion of B cell proliferation and the production of antigen-specific antibodies (42). **In this regard, we identified an increased humoral immunity in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice that was reflected by an increase in circulating IgM and IgG and circulating anti-insulin autoantibodies.** Recent gene expression profiling in DO11;RIP-mOVA mice (a model of type 1 diabetes) has identified a T<sub>FH</sub> cell gene signature in islet-specific T cells and has shown that transgenic DO11 T cells with a T<sub>FH</sub> signature from diabetic animals transfer diabetes to RIP-OVA recipients (26). Importantly, increased T<sub>FH</sub> cells are linked with the development of autoimmunity and T<sub>FH</sub> cells are over-represented in patients with type 1 diabetes (26; 52). The production of T<sub>FH</sub> cells and their homing to germinal centres is dependent on autocrine IL-21 that signals via JAK-1/3 and STAT-3 (53). STAT-3 is required for both T<sub>FH</sub> and germinal

centre B cell differentiation and STAT-3 gain-of-function mutations that increase T<sub>FH</sub> cells and autoantibody production may be associated with type 1 diabetes in humans (42; 54). Moreover, *along with Il2, Il21* is a candidate gene for the diabetes susceptibility locus *Idd3* and IL-21 signaling is required for diabetes development in NOD mice (55). JAK-1/3 and STAT-3 are *bona fide* substrates of PTPN2 (21) and the inducible hematopoietic deletion of *Ptpn2* in adult C57BL/6 mice is accompanied by heightened IL-21-induced STAT-3 signalling in T<sub>FH</sub> cells *ex vivo* (22). Therefore, in addition to lowering the threshold for TCR-instigated responses to self-antigen by enhancing LCK signalling, PTPN2-deficiency may drive STAT-3 signalling in CD4<sup>+</sup> T cells to enhance the formation of T<sub>FH</sub> cells and the maturation of B cells to facilitate disease progression in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice.

Beyond spontaneously developing type 1 diabetes, NOD mice also exhibit T cell-mediated autoimmunity against other tissues, including the thyroid gland and especially the lacrimal and salivary glands, mimicking Sjogren's syndrome (43; 44). Moreover, young NOD mice also develop low levels of colitis due to disturbed tolerance towards autologous commensal gut antigens (45). This is accompanied by an increase in activated CD4<sup>+</sup> T cells and T<sub>H17</sub> cells in the colonic lamina propria (45). In addition to promoting type 1 diabetes, T cell-specific PTPN2 deficiency in NOD mice was accompanied by marked lymphocytic infiltrates in salivary glands and the formation of what resembled ectopic lymphoid-like structures that included T cells and B cells. Ectopic lymphoid-like structures develop at sites of inflammation, can form functional germinal centres and contribute to disease pathogenesis. Importantly ectopic lymphoid-like structures are seen in the salivary glands of patients with Sjogren's syndrome (56). Similarly, PTPN2 deficiency resulted in widespread immune infiltrates and the formation of lymphoid clusters, probably ectopic lymphoid-like structures that

are a pathologic hallmark of inflammatory bowel disease, including Crohn's disease (57). Consistent with this, lymphocytic infiltrates in mesenteric lymph nodes included not only CD44<sup>hi</sup>CD62L<sup>lo</sup> CD4<sup>+</sup> T cells, but also T<sub>FH</sub> cells and germinal centre B cells. In addition, there was a marked infiltration of activated/cytotoxic CD8<sup>+</sup> T cells and CD4<sup>+</sup> T cells with a predominant T<sub>H1</sub> phenotype in the lamina propria of *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. Although previous studies have found that in dextran sodium sulfate or T-cell transfer-induced colitis models PTPN2 deficiency resulted in the induction of both T<sub>H1</sub> and T<sub>H17</sub> cells and the impaired induction of T<sub>reg</sub> cells (36), we found that T<sub>H17</sub> and T<sub>reg</sub> cells were unaltered in the colons of 5 week-old pre-diabetic mice and the generation of T<sub>H17</sub> and T<sub>reg</sub> cells *ex vivo* was not affected by PTPN2-deficiency. Nonetheless, we cannot exclude the possibility that such alterations may occur as disease progresses.

The findings of our study underscore the importance of PTPN2 in tuning T cell responses for the maintenance of T cell tolerance and prevention of autoimmunity. Moreover, as PTPN2 deficiency in T cells alone exacerbated the development of both type 1 diabetes and colitis in NOD mice, our results argue for perturbations in T cell function being causally involved in the early onset type 1 diabetes and Crohn's associated with *PTPN2* loss of function SNPs in humans. Importantly, the findings of this study suggest that beyond driving type 1 diabetes or Crohn's disease, PTPN2 loss of function SNPs in humans might also contribute to the development of associated comorbidities.

## **AUTHOR CONTRIBUTIONS**

Conceptualization –F.W. and T.T.; Methodology, F.W., T.B., P.K.G., Y.L., G.W.J., D.Y., A.B., S.A.J., T.K., and T.T., ; Investigation – F.W., T.B., P.K.G., Y.L., and G.W.J.. Writing – Original Draft, F.W. T.B., and T.T.; Writing – Review & Editing, F.W., T.B., P.K.G., Y.L., G.W.J., D.Y., A.B., S.A.J., T.K., and T.T.; Funding Acquisition, T.T.

## **ACKNOWLEDGEMENTS**

We thank Alexandra Ziegler and Lauren Stanton for technical support, Rhana Kostoulas for animal husbandry and Robyn Slattery for providing the NOD/Lt mice. This work was supported by the NHMRC of Australia (1047055 to T.T.). T.T is an NHMRC Principal Research Fellow (1103037).

“Dr. Tony Tiganis is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.”

## **CONFLICTS OF INTEREST**

None declared.

## REFERENCES

1. Cho JH, Feldman M: Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. *Nat Med* 2015;21:730-738
2. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszkó JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu-Tirgoviste C, Simmonds MJ, Heward JM, Gough SC, Dunger DB, Wicker LS, Clayton DG: Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet* 2007;39:857-864
3. Consortium WTCC: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007;447:661-678
4. Espino-Paisan L, de la Calle H, Fernandez-Arquero M, Figueredo MA, de la Concha EG, Urcelay E, Santiago JL: A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes. *Immunogenetics* 2011; Epub ahead of print
5. Festen EA, Goyette P, Green T, Boucher G, Beauchamp C, Trynka G, Dubois PC, Lagace C, Stokkers PC, Hommes DW, Barisani D, Palmieri O, Annesse V, van Heel DA, Weersma RK, Daly MJ, Wijmenga C, Rioux JD: A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. *PLoS Genet* 2011;7:e1001283
6. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Todhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC, Wellcome Trust Case Control C, Cardon L, Mathew CG: Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. *Nat Genet* 2007;39:830-832
7. Thompson SD, Sudman M, Ramos PS, Marion MC, Ryan M, Tsoras M, Weiler T, Wagner M, Keddache M, Haas JP, Mueller C, Prahalad S, Bohnsack J, Wise CA, Punaro M, Zhang D, Rose CD, Comeau ME, Divers J, Glass DN, Langefeld CD: The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. *Arthritis Rheum* 2010;62:3265-3276
8. Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J, Martin P, Comeau ME, Sajuthi S, Andrews R, Brown M, Chen WM, Concannon P, Deloukas P, Edkins S, Eyre S, Gaffney PM, Guthery SL, Guthridge JM, Hunt SE, James JA, Keddache M, Moser KL, Nigrovic PA, Onengut-Gumuscu S, Onslow ML, Rose CD, Rich SS, Steel KJ, Wakeland EK, Wallace CA, Wedderburn LR, Woo P, Boston Children's JIAR, British Society of P, Adolescent Rheumatology Study G, Childhood Arthritis Prospective S, Childhood Arthritis Response to Medication S, German Society for Pediatric R, Study JIAGE, Registry NJG, Study T, United Kingdom Juvenile Idiopathic Arthritis Genetics C, Bohnsack JF, Haas JP, Glass DN, Langefeld CD, Thomson W, Thompson SD: Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. *Nat Genet* 2013;45:664-669
9. Long SA, Cerosaletti K, Wan JY, Ho JC, Tatum M, Wei S, Shilling HG, Buckner JH: An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4+ T cells. *Genes Immun* 2011;12:116-125
10. Okuno M, Ayabe T, Yokota I, Musha I, Shiga K, Kikuchi T, Kikuchi N, Ohtake A, Nakamura A, Nakabayashi K, Okamura K, Momozawa Y, Kubo M, Suzuki J, Urakami T, Kawamura T, Amemiya S, Ogata T, Sugihara S, Fukami M, Japanese Study Group

of Insulin Therapy for C, Adolescent D: Protein-altering variants of PTPN2 in childhood-onset Type 1A diabetes. *Diabet Medicine* 2018;35:376-380

11. Scharl M, Mwinyi J, Fischbeck A, Leucht K, Eloranta JJ, Arikkat J, Pesch T, Kellermeier S, Mair A, Kullak-Ublick GA, Truninger K, Noreen F, Regula J, Gaj P, Pittet V, Mueller C, Hofmann C, Fried M, McCole DF, Rogler G: Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. *Inflamm Bowel Dis* 2012;18:900-912

12. Scharl M, Wojtal KA, Becker HM, Fischbeck A, Frei P, Arikkat J, Pesch T, Kellermeier S, Boone DL, Weber A, Loessner MJ, Vavricka SR, Fried M, McCole DF, Rogler G: Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. *Inflamm Bowel Dis* 2012;18:1287-1302

13. You-Ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, Jothy S, Lapp WS, Tremblay ML: Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. *J Exp Med* 1997;186:683-693

14. Wiede F, Hui Chew S, van Vliet C, Poulton IJ, Kyparissoudis K, Sasmono T, Loh K, Tremblay ML, Godfrey DI, Sims NA, Tiganis T: Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in Ptpn2-deficient mice. *PlosOne* 2012;7:e36703

15. Wiede F, Shields BJ, Chew SH, Kyparissoudis K, van Vliet C, Galic S, Tremblay ML, Russell SM, Godfrey DI, Tiganis T: T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. *J Clin Invest* 2011;121:4758-4774

16. van Vliet C, Bukczynska PE, Puryer MA, Sadek CM, Shields BJ, Tremblay ML, Tiganis T: Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. *Nat Immunol* 2005;6:253-260

17. Wiede F, Dudakov JA, Lu K-H, Dodd GT, Butt T, Godfrey DI, Strasser A, Boyd RL, Tiganis T: PTPN2 regulates T cell lineage commitment and  $\alpha\beta$  versus  $\gamma\delta$  specification. *J Exp Med* 2017;214:2733-2758

18. Wiede F, La Gruta NL, Tiganis T: PTPN2 attenuates T-cell lymphopenia-induced proliferation. *Nat Commun* 2014;5:3073

19. Wiede F, Ziegler A, Zehn D, Tiganis T: PTPN2 restrains CD8(+) T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice. *J Autoimmun* 2014;53:105-114

20. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ: The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. *Curr Biol* 2002;12:446-453.

21. Tiganis T, Bennett AM: Protein tyrosine phosphatase function: the substrate perspective. *Biochem J* 2007;402:1-15

22. Wiede F, Sacirbegovic F, Leong YA, Yu D, Tiganis T: PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity. *J Autoimmun* 2017;76:85-100

23. Penafuerte C, Feldhammer M, Mills JR, Vinette V, Pike KA, Hall A, Migon E, Karsenty G, Pelletier J, Zogopoulos G, Tremblay ML: Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFN $\gamma$  signaling. *Oncoimmunology* 2017;6:e1321185

24. Santin I, Moore F, Colli ML, Gurzov EN, Marselli L, Marchetti P, Eizirik DL: PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic beta-cell apoptosis via regulation of the BH3-only protein Bim. *Diabetes* 2011;60:3279-3288

25. Pearson JA, Wong FS, Wen L: The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. *J Autoimmun* 2016;66:76-88

26. Kenefeck R, Wang CJ, Kapadi T, Wardzinski L, Attridge K, Clough LE, Heuts F, Kogimtzis A, Patel S, Rosenthal M, Ono M, Sansom DM, Narendran P, Walker LS: Follicular helper T cell signature in type 1 diabetes. *J Clin Invest* 2015;125:292-303
27. Driver JP, Serreze DV, Chen YG: Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. *Semin Immunopathol* 2011;33:67-87
28. Baxter AG, Koulmanda M, Mandel TE: High and low diabetes incidence nonobese diabetic (NOD) mice: origins and characterisation. *Autoimmunity* 1991;9:61-67
29. Marino E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, McKenzie C, Kranich J, Oliveira AC, Rossello FJ, Krishnamurthy B, Nefzger CM, Macia L, Thorburn A, Baxter AG, Morahan G, Wong LH, Polo JM, Moore RJ, Lockett TJ, Clarke JM, Topping DL, Harrison LC, Mackay CR: Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. *Nat Immunol* 2017;18:552-562
30. Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, Fleming SA, Leiter EH, Shultz LD: B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. *J Exp Med* 1996;184:2049-2053
31. Ziegler AI, Le Page MA, Maxwell MJ, Stolp J, Guo H, Jayasimhan A, Hibbs ML, Santamaria P, Miller JF, Plebanski M, Silveira PA, Slaterry RM: The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development. *Diabetologia* 2013;56:2659-2668
32. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS: Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. *Nature* 2005;435:220-223
33. Turley S, Poirot L, Hattori M, Benoist C, Mathis D: Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. *J Exp Med* 2003;198:1527-1537
34. Gregori S, Giarratana N, Smiroldo S, Adorini L: Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. *J Immunol* 2003;171:4040-4047
35. Katz JD, Benoist C, Mathis D: T helper cell subsets in insulin-dependent diabetes. *Science* 1995;268:1185-1188
36. Spalinger MR, Kasper S, Chassard C, Raselli T, Frey-Wagner I, Gottier C, Lang S, Atrott K, Vavricka SR, Mair F, Becher B, Lacroix C, Fried M, Rogler G, Scharl M: PTPN22 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis. *Mucosal Immunol* 2015;8:918-929
37. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H: Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. *J Immunol* 2003;170:4886-4890
38. ten Hoeve J, Ibarra-Sanchez MJ, Fu Y, Zhu W, Tremblay M, David M, Shuai K: Identification of a nuclear Stat1 protein tyrosine phosphatase. *Mol Cell Biol* 2002;22:5662-5668
39. Ohkura N, Kitagawa Y, Sakaguchi S: Development and maintenance of regulatory T cells. *Immunity* 2013;38:414-423
40. Levine AG, Arvey A, Jin W, Rudensky AY: Continuous requirement for the TCR in regulatory T cell function. *Nat Immunol* 2014;15:1070-1078
41. Smith MJ, Simmons KM, Cambier JC: B cells in type 1 diabetes mellitus and diabetic kidney disease. *Nat Rev Nephrol* 2017;13:712-720

42. Tangye SG, Ma CS, Brink R, Deenick EK: The good, the bad and the ugly - TFH cells in human health and disease. *Nat Rev Immunol* 2013;13:412-426
43. Damotte D, Colomb E, Cailleau C, Brousse N, Charreire J, Carnaud C: Analysis of susceptibility of NOD mice to spontaneous and experimentally induced thyroiditis. *Eur J Immunol* 1997;27:2854-2862
44. Robinson CP, Yamachika S, Bounous DI, Brayer J, Jonsson R, Holmdahl R, Peck AB, Humphreys-Beher MG: A novel NOD-derived murine model of primary Sjogren's syndrome. *Arthritis Rheum* 1998;41:150-156
45. Alam C, Valkonen S, Palagani V, Jalava J, Eerola E, Hanninen A: Inflammatory tendencies and overproduction of IL-17 in the colon of young NOD mice are counteracted with diet change. *Diabetes* 2010;59:2237-2246
46. Bao YK, Weide LG, Ganesan VC, Jakhar I, McGill JB, Sahil S, Cheng AL, Gaddis M, Drees BM: High prevalence of comorbid autoimmune diseases in adults with type 1 diabetes from the HealthFacts database. *J Diabetes* 2018;
47. Pugliese A: Autoreactive T cells in type 1 diabetes. *J Clin Invest* 2017;127:2881-2891
48. Walker LS, von Herrath M: CD4 T cell differentiation in type 1 diabetes. *Clin Exp Immunol* 2016;183:16-29
49. Yi Z, Lin WW, Stunz LL, Bishop GA: The adaptor TRAF3 restrains the lineage determination of thymic regulatory T cells by modulating signaling via the receptor for IL-2. *Nat Immunol* 2014;15:866-874
50. Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, Tisch RM, Tedder TF: B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. *J Immunol* 2008;180:2863-2875
51. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet Anti CDSG: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. *N Engl J Med* 2009;361:2143-2152
52. Linterman MA, Rigby RJ, Wong RK, Yu D, Brink R, Cannons JL, Schwartzberg PL, Cook MC, Walters GD, Vinuesa CG: Follicular helper T cells are required for systemic autoimmunity. *J Exp Med* 2009;206:561-576
53. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C: A fundamental role for interleukin-21 in the generation of T follicular helper cells. *Immunity* 2008;29:127-137
54. Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Lango Allen H, De Franco E, McDonald TJ, Rajala H, Ramelius A, Barton J, Heiskanen K, Heiskanen-Kosma T, Kajosaari M, Murphy NP, Milenkovic T, Seppanen M, Lernmark A, Mustjoki S, Otonkoski T, Kere J, Morgan NG, Ellard S, Hattersley AT: Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. *Nat Genet* 2014;46:812-814
55. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ: IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. *Proc Natl Acad Sci U S A* 2008;105:14028-14033
56. Jonsson MV, Skarstein K, Jonsson R, Brun JG: Serological implications of germinal center-like structures in primary Sjogren's syndrome. *J Rheumatol* 2007;34:2044-2049
57. McNamee EN, Rivera-Nieves J: Ectopic Tertiary Lymphoid Tissue in Inflammatory Bowel Disease: Protective or Provocateur? *Front Immunol* 2016;7:308



## FIGURE LEGENDS

### **Figure 1. PTPN2-deficiency in T cells promotes the early onset of type I diabetes in**

***Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice. a-b)** Female and male *Ptpn2<sup>fl/fl</sup>.NOD*, *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD*, *Lck-Cre;Ptpn2<sup>fl/+</sup>.NOD* and NOD/Lt mice were monitored for survival and diabetes incidence (urine glucose  $\geq 55$  mmol/l; blood glucose  $> 18$  mmol/l). **c)** Pancreata from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice were fixed in formalin and processed for histological assessment (hematoxylin and eosin: H&E) and **d)** the severity of insulitis was determined histologically. **e)** Formalin fixed pancreata were processed for immunohistochemistry staining for B220 and CD3. **f) Pancreata from 12-15 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/+</sup>.NOD* mice were fixed in formalin and processed for histological assessment and g) the severity of insulitis was determined histologically.** Results in (a-e) are representative of two independent experiments. The percent of islets graded 0-4 and those with invasive insulitis (grades 3 and 4) in (d) and (g) were determined for the indicated number of mice. Significant differences in invasive insulitis (means  $\pm$  SEM) were determined using -tailed Mann-Whitney *U* test (non-parametric); \*\**p* < 0.01. Statistical analyses on Kaplan-Meier estimates in (a-b) (\**p* < 0.05, \*\**p* < 0.01, \*\*\*\**p* < 0.0001) were performed using a Log-rank (Mantel-Cox) test with one degree of freedom.

### **Figure 2. Increased effector/memory T cells and T<sub>H1</sub> cells in *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD***

***mice.*** Lymphocytes from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice were harvested from **a)** spleen, **b)** inguinal lymph nodes (LN), **c)** pancreatic lymph nodes (panLN) and **d-f)** pancreata and **a-d)** stained for CD4, CD8, CD62L and CD44 or **e)** were stimulated with 20 ng/ml PMA/ 1  $\mu$ g/ml Ionomycin (4 h)

in the presence of Brefeldin A/Monensin, fixed and then permeabilised and stained for CD4, CD8, IL-4, IFN- $\gamma$  and analysed by flow cytometry. **f)** Pancreatic lymphocytes were stained for CD8, CD62L, CD44, CD49d, KLRG1 and CD127 and analysed by flow cytometry. Representative contour-plots in (a, e, f) are shown. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments. In (a-f) significance was determined using 2-tailed Mann-Whitney U Test; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

**Figure 3. Adoptive transfer of PTPN2-deficient naïve CD8<sup>+</sup> T cells promotes type 1 diabetes in NOD mice.** **a)**  $1 \times 10^7$  naïve CD8<sup>+</sup> T cells (CD44<sup>lo</sup>CD62L<sup>hi</sup>) from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were adoptively transferred into replete female NOD hosts, which were monitored for survival and diabetes incidence (urine glucose  $\geq 55$  mmol/l). **b)** Pancreata were fixed in formalin and processed for histological assessment and the severity of insulitis determined for the indicated number of mice. **c)** Pancreata from naïve CD8<sup>+</sup> T cell recipient NOD mice from (b) were fixed in formalin and processed for histological assessment.

**Figure 4. Increased regulatory T cells in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice.** **a)** Thymocytes from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were stained for CD4, CD25 and intracellular FoxP3 and the numbers of CD4<sup>+</sup>FoxP3<sup>+</sup>CD25<sup>hi/lo</sup> T cells were quantified by flow cytometry. **b)** PanLN cells and pancreatic lymphocytes from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were stained for CD4 and intracellular FoxP3 and the numbers of CD4<sup>+</sup>FoxP3<sup>+</sup> T cells were quantified by flow cytometry. **c-**

**d)** PanLN cells and pancreatic lymphocytes from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were stained for CD4, CD25, CD62L, CD44 and intracellular FoxP3 and the numbers of central-resting (CD44<sup>hi</sup>CD62L<sup>hi</sup>) and effector-like (CD44<sup>hi</sup>CD62L<sup>lo</sup>) T cells were quantified by flow cytometry. **e)** Ratios of pancreatic CD4<sup>+</sup>FoxP3<sup>+</sup> T<sub>regs</sub> and CD4<sup>+</sup>CD44<sup>hi</sup>CD62L<sup>lo</sup> effector/memory (Eff/mem) T cells were determined by flow cytometry. **f)** FACS-purified naïve CD4<sup>+</sup>CD25<sup>lo</sup> lymph node T cells (5x10<sup>4</sup>) from 5 week old female pre-diabetic NOD mice were stained with CTV (Cell Tracker Violet) and incubated with  $\alpha$ -CD3 (1  $\mu$ g/ml) in the presence of irradiated accessory splenocytes and FACS-purified CD4<sup>+</sup>CD25<sup>hi</sup> T<sub>regs</sub> (5x10<sup>4</sup>-0.625x10<sup>4</sup>) from 5 week old female pre-diabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. After 72 h proliferation was assessed by flow cytometry monitoring for CTV dilution. Representative contour-plots in and representative histograms in are shown. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments. In (a-d) significance was determined using 2-tailed Mann-Whitney U Test; \*p < 0.05; \*\*p < 0.01.

**Figure 5. Enhanced T<sub>FH</sub> and GC B cells in *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice. a-b)**

Lymphocytes were harvested from spleen, inguinal lymph nodes and panLNs from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice were stained for **a)** CD4, CD44, CXCR5 and CD274 (PD-1) mice to identify CD4<sup>+</sup>CD44<sup>hi</sup>CXCR5<sup>hi</sup>PD-1<sup>hi</sup> follicular helper (T<sub>fh</sub>) T cells or **b)** B220, GL-7 and CD95 (Fas) to identify B220<sup>+</sup>GL-7<sup>hi</sup>Fas<sup>hi</sup> germinal centre (GC) B cells and analysed by flow cytometry. **c)** Serum immunoglobulins from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice and **d)** serum IAA (insulin autoantibodies) from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>*.NOD and *Lck-*

*Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice and 12 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/+</sup>.NOD* mice were determined by ELISA. Representative contour-plots in (a, b) are shown. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments. In (a-d) significance was determined using 2-tailed Mann-Whitney U Test; \*\*p < 0.01, \*\*\*p < 0.001.

**Figure 6. Type 1 diabetes in *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice is accompanied by systemic inflammation and autoimmunity.** **a)** Serum cytokines in 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice were determined by flow cytometry using a BD Cytokine Bead Array (BD Biosciences). **b)** Salivary glands from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice were fixed in formalin and processed for histological assessment (H&E and immunohistochemistry staining for B220 and CD3). **c)** Colons from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice were assessed for length and processed for histology. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments. In (a, c) significance was determined using 2-tailed Mann-Whitney U Test; \*\*p < 0.01.

**Figure 7. Colitis in *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice.** Lymphocytes from 5 week old female prediabetic *Ptpn2<sup>fl/fl</sup>.NOD* and *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* mice harvested from **a)** mesenteric lymph nodes and **b-c)** lamina propria and were stained for **a, b)** CD4, CD8, CD62L and CD44 or **a)** CD4, CD44, CXCR5 and CD274 (PD-1) and B220, GL-7 and CD95 (Fas) and analysed by flow cytometry. **c)** Lamina propria lymphocytes were stimulated with 20 ng/ml PMA/1  $\mu$ g/ml Ionomycin (4 h) in the presence of Brefeldin A/Monensin, fixed and then permeabilised and stained for CD4, CD8, IFN- $\gamma$  and IL-

17A and analysed by flow cytometry. Representative contour-plots or dot-plots in (b, c) are shown. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments. In (a-c) significance was determined using 2-tailed Mann-Whitney U Test; \* $p < 0.05$ , \*\* $p < 0.01$ .




Figure 1

Figure 1

190x275mm (300 x 300 DPI)




Figure 2

190x275mm (300 x 300 DPI)




Figure 3

Figure 3

190x275mm (300 x 300 DPI)






Figure 4

Figure 4

190x275mm (300 x 300 DPI)




Figure 5

Figure 5

190x275mm (300 x 300 DPI)




Figure 6

Figure 6

190x275mm (300 x 300 DPI)




Figure 7

Figure 7

190x275mm (300 x 300 DPI)

## SUPPLEMENTAL MATERIALS

### **T cell-specific PTPN2-deficiency in NOD mice accelerates the development of type 1 diabetes and autoimmune co-morbidities.**

Florian Wiede <sup>1,2,3\*</sup>, Tom Brodnicki <sup>4,5</sup>, Pei Kee Goh <sup>1,2,3</sup>, Yew A. Leong <sup>2</sup>, Gareth W. Jones <sup>6,7,8</sup>, Di Yu <sup>2</sup>, Alan G. Baxter <sup>9</sup>, Simon A. Jones <sup>6,7</sup>, Tom Kay <sup>4,5</sup> and Tony Tiganis <sup>1,2,3\*</sup>

<sup>1</sup>Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia, <sup>2</sup>Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, <sup>3</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia, <sup>4</sup>St. Vincent's Institute, Fitzroy, Victoria 3065, Australia, <sup>5</sup> Department of Medicine, St. Vincent's Hospital, The University of Melbourne, Fitzroy, Victoria 3065, Australia, <sup>6</sup>Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK, <sup>7</sup>Systems Immunity University Research Institute, Cardiff University, Cardiff, Wales, UK, <sup>8</sup>School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK, <sup>9</sup>Comparative Genomics Centre, James Cook University, Townsville, QLD, Australia.

### ***Generation of *Lck-Cre;Ptpn2<sup>fl/fl</sup>*.NOD mice***

*Lck-Cre;Ptpn2<sup>fl/fl</sup>*.C57BL/6J mice (1; 2) were backcrossed onto the NOD/Lt genetic background (3) for 11 generations. DNA samples were extracted from tail biopsies and genotyped by standard PCR using oligos specific for the *Ptpn2* floxed allele (*forward primer*: 5' GAA TTC CAG GAC AGC CAA GG 3'; *reverse primer*: 5' CTG CTC TTA AAG GGG ATC AGG 3') and the *Cre* transgene (*forward primer*: 5' ATG TCC AAT TTA CTG ACC 3'; *reverse primer*: 5' CGC CGC ATA ACC AGT GAA AC 3'). Amplified products were visualized by gel electrophoresis to distinguish the *Ptpn2* floxed allele (size = 1300 bp) and *wild-type* allele (1100 bp) or the *Lck-Cre* transgene (350 bp). A genome-wide screen was performed by the Australian Genome Research Facility using the iPLEX GOLD chemistry and the Sequenom MassArray spectrometer for SNP genotyping. Data was analyzed using the GeneChip Targeted Genotyping System Software. 11<sup>th</sup> generation backcrossed NOD mice heterozygous for the *Ptpn2* floxed allele and positive for the *Lck-Cre* transgene were of the NOD genotype across the whole genome except for those markers encompassing the C57BL/6-derived *Ptpn2* floxed allele (chromosome 18) and the C57BL/6-derived *Lck-Cre* transgene (chromosome 15).

### ***Flow cytometry***

The following antibodies from BD Biosciences, eBioscience or BioLegend were used for flow cytometry: Phycoerythrin (PE) or peridinin-chlorophyll cyanine 5.5 (PerCP-Cy5.5)-conjugated CD3 (145-2C11); PerCP-Cy5.5 or phycoerythrin-cyanine 7 (PE-Cy7)-conjugated CD4 (RM4-5); Pacific Blue-conjugated (PB) or allophycocyanin-cyanine 7 (APC-Cy7)-conjugated CD8 (53-6.7); PE or APC-Cy7-conjugated CD25 (PC61); Fluorescein isothiocyanate (FITC) or V450-conjugated CD44 (IM7); APC-Cy7-conjugated CD45 (30-F11); APC or APC-Cy7-conjugated CD45R (B220; RA3-6B2); biotin-conjugated CD49d (9C10; MFR4.B); PE-cyanine 5 (PE-Cy5)-conjugated TCR- $\delta$  (GL3); PE-Cy7 or APC-

conjugated CD62L (MEL-14); PE-conjugated CD127 (SB/199); biotin-conjugated CD185 (CXCR5; 2G8); PE-Cy7-conjugated CD279 (PD-1, RMP1-14); APC-conjugated KLRG1 (2F1), PE or FITC-conjugated GL-7 (GL-7); PE-Cy7 or PE-conjugated IFN $\gamma$  (XMG1.2); PE or V421-conjugated IL-17A (TC11-18H10.1) FITC-conjugated IL-4 (11B11), V450-conjugated FoxP3 (clone MF23). APC- or PE-Cy7-conjugated streptavidin were used to detect cells stained with biotinylated antibodies.

### ***Histological assessment of pancreas and salivary glands infiltrating lymphocytes***

To detect CD45R<sup>+</sup> (B220<sup>+</sup>) B cells and CD3<sup>+</sup> T cells, sections were deparaffinized and rehydrated. Antigen retrieval was performed in citrate acid buffer (pH 6.0) at 95°C for 20 min. Sections were blocked with 20% (v/v) normal goat serum in 0.1 M phosphate buffer and 0.2% (v/v) Triton X-100 for 1 h at room temperature. Sections were incubated overnight at 4°C with  $\alpha$ -CD3 $\epsilon$  (1:500; RAM 34 clone, 14-0341, eBioscience) or  $\alpha$ -CD45R (1:400; RA3-6B2, BD Biosciences). CD45R<sup>+</sup> (B220<sup>+</sup>) B cells and CD3<sup>+</sup> T cells were visualized using rabbit or rat IgG VECTORSTAIN ABC Elite and DAB (3,3'-diaminobenzidine) Peroxidase Substrate Kits (Vector Laboratories) and counterstained with hematoxylin. Sections were visualized on a Zeiss Axioskop 2 mot plus microscope (Carl Zeiss) and Aperio imaging software.

### ***Isolation of intraepithelial and lamina propria lymphocytes***

For the isolation of intraepithelial (IEL) and lamina propria (4) lymphocytes colons excised from 5 week old prediabetic *Lck-Cre;Ptpn2<sup>fl/fl</sup>.NOD* and *Ptpn2<sup>fl/fl</sup>.NOD* littermate control mice was cut into 0.5–1 cm pieces and incubated twice with Ca<sup>2+</sup> and Mg<sup>2+</sup>-free HBSS supplemented with 5% (v/v) FBS, 2 mM EDTA, 0.15 mg/ml DTT (dithiothreitol) and 10mM HEPES shaking at 250 rpm for 15 min at 37°C to isolate intraepithelial lymphocytes. Intestine pieces were further digested in Ca<sup>2+</sup> and Mg<sup>2+</sup>-containing HBSS supplemented with 5% (v/v)

FBS, 1.5 mg/ml Collagenase D, 0.02 mg/ml Dnase I shaking at 250 rpm for 1h at 37 °C. Lymphocytes from digested colon pieces were enriched using a two-layer Percoll gradient at 40 and 80% (v/v) in DMEM supplemented with 10% (v/v) FBS.

### ***Antigen-induced arthritis (AIA)***

8-12 week-old C57BL/6J male mice were immunized subcutaneously with 100 µl mBSA (1 mg/ml; Sigma-Aldrich) emulsified in an equal volume of Complete Freund's Adjuvant (CFA). Mice also received 160 ng of heat-inactivated *Bordetella pertussis* toxin as a single intraperitoneal injection (Sigma-Aldrich). One week later, mice received an identical subcutaneous booster immunization of methylated BSA (mBSA) in CFA. 21 days after the initial immunization, inflammatory arthritis was induced by intraarticular administration of 10 µl mBSA (10 mg/ml) into the right knee joint. Arthritis development by measuring knee joint diameters using a POCO 2T micrometer (Kroeplin).

### ***Histological assessment of joint inflammation***

Knee joints were fixed in 10% (v/v) neutral buffered formal saline (Sigma-Aldrich) and decalcified in 10% (v/v) formic acid at 4°C before embedding in paraffin. Parasagittal serial sections (7 µm) were stained with haematoxylin (VWR International), fast green and safranin O (both from Sigma-Aldrich) for histological evaluation of joint pathology. Two observers blinded to the experimental groups scored the sections for sub-synovial inflammation (0 = normal to 5 = ablation of adipose tissue due to leukocyte infiltrate), synovial exudate (0 = normal to 3 = substantial number of cells with large fibrin deposits), synovial hyperplasia (0 = normal with 1-3 cells thick to 3 = over 3 layers thick with overgrowth onto joint surfaces with evidence of cartilage/bone erosion), and cartilage/bone erosion (0 = normal to 3 = destruction of a significant part of the bone). Joint histopathology in pre-diabetic 5 week old *Lck-*



Cre;*Ptpn2<sup>fl/fl</sup>*.NOD and *Ptpn2<sup>fl/fl</sup>*.NOD littermate control mice was compared to C57BL/6J mice with antigen-induced arthritis.

### ***In vitro generation of $T_{H1}$ , $T_{reg}$ and $T_{H17}$ cells***

FACS-purified naïve  $CD4^{+}CD44^{lo}CD62L^{hi}CD25^{lo}$  lymph node T cells ( $5 \times 10^4$ ) isolated from 6-8 week old *Lck-Cre;Ptpn2<sup>fl/fl</sup>* and *Ptpn2<sup>fl/fl</sup>* littermate control mice were stimulated with plate-bound  $\alpha$ -CD3 $\epsilon$  (1  $\mu$ g/ml) in the presence of soluble  $\alpha$ -CD28 (10  $\mu$ g/ml) in complete T cell medium overnight in 96-well round bottom plates. For the generation of  $T_{H1}$  cells 10  $\mu$ g/ml soluble  $\alpha$ -IL-4 (clone BVD4-1D11, WEHI) was added and for the generation of  $T_{H17}$  cells 10  $\mu$ g/ml soluble  $\alpha$ -IL-4 (clone BVD4-1D11, WEHI) and 10  $\mu$ g/ml soluble  $\alpha$ -IFN $\gamma$  (clone XMG1.2, WEHI) were added. Cells were harvested and transferred to new 96-well round bottom plates and incubated with IL-2 (10 ng/ml) alone or various concentrations of IL-12 to generate  $T_{H1}$  cells or TGF $\beta$  (5 ng/ml) to generate  $T_{reg}$  cells. To generate  $T_{H17}$  cells, cells were incubated in IL-6 (50 ng/ml) and TGF $\beta$  (1 ng/ml) in the absence of IL-2. Cells were harvested at day 4 and 5 and processed for flow cytometry.

### ***Treg suppression assay***

FACS-purified naïve  $CD4^{+}CD25^{lo}$  responder T cells ( $5 \times 10^4$ ) were labelled with CTV (Cell Tracker Violet, Molecular Probes) and cultured for 72 h with X-ray irradiated (4,000 rad) splenocytes ( $5 \times 10^4$ ) and 1  $\mu$ g/ml  $\alpha$ -CD3 $\epsilon$  (145-2C11) in the presence of the indicated ratio of FACS-purified  $CD4^{+}CD25^{hi}$  suppressor T cells.

### **SUPPLEMENTAL REFERENCES:**

1. Loh K, Fukushima A, Zhang X, Galic S, Briggs D, Enriori PJ, Simonds S, Wiede F, Reichenbach A, Hauser C, Sims NA, Bence KK, Zhang S, Zhang ZY, Kahn BB, Neel BG, Andrews ZB, Cowley MA, Tiganis T: Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. *Cell Metab* 2011;14:684-699

2. Wiede F, Shields BJ, Chew SH, Kyparissoudis K, van Vliet C, Galic S, Tremblay ML, Russell SM, Godfrey DI, Tiganis T: T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. *J Clin Invest* 2011;121:4758-4774
3. Slattery RM, Kjer-Nielsen L, Allison J, Charlton B, Mandel TE, Miller JF: Prevention of diabetes in non-obese diabetic I-Ak transgenic mice. *Nature* 1990;345:724-726
4. Ziegler AI, Le Page MA, Maxwell MJ, Stolp J, Guo H, Jayasimhan A, Hibbs ML, Santamaria P, Miller JF, Plebanski M, Silveira PA, Slattery RM: The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development. *Diabetologia* 2013;56:2659-2668

## SUPPLEMENTARY FIGURE LEGENDS

### ***Supplementary figure 1. PTPN2 deficiency enhances the in vitro generation of $T_{H1}$ cells.***

FACS-purified naïve  $CD4^+CD44^{lo}CD62L^{hi}CD25^{lo}$  lymph node T cells from  $Ptpn2^{fl/fl}$  and  $Lck-Cre;Ptpn2^{fl/fl}$  mice were cultured under  $T_{H1}$  polarising conditions in the presence of IL-2 (10 ng/ml) and various concentrations of IL-12. At day 4 cells were harvested and stained for intracellular IFN $\gamma$  and the percentage of IFN $\gamma^+$   $T_{H1}$  cells was determined by flow cytometry.

**b-c)** FACS-purified naïve  $CD4^+CD44^{lo}CD62L^{hi}CD25^{lo}$  lymph node T cells from  $Ptpn2^{fl/fl}$  and  $Lck-Cre;Ptpn2^{fl/fl}$  mice were incubated with plate-bound  $\alpha$ -CD3 $\epsilon$  (5  $\mu$ g/ml)/CD28 (5  $\mu$ g/ml) for 48 h and then stimulated with **b)** 50 U/ml IFN $\gamma$  or **c)** 10 ng/ml IL-12 for the indicated times and processed for immunoblotting. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments. Significance was determined using Student's T-test; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

***Supplementary figure 2. Regulatory T cell development in vivo and ex vivo.*** a) Inguinal lymph node cells and splenocytes from 5 week old female prediabetic  $Ptpn2^{fl/fl}$ .NOD and  $Lck-Cre;Ptpn2^{fl/fl}$ .NOD mice were stained for CD4, CD25, CD62L, CD44 and intracellular FoxP3

and the numbers of central-resting ( $CD44^{hi}CD62L^{hi}$ ), and effector-like ( $CD44^{hi}CD62L^{lo}$ )  $T_{reg}$  cells were quantified by flow cytometry. **b)** FACS-purified naïve  $CD4^{+}CD44^{lo}CD62L^{hi}CD25^{lo}$  lymph node T cells were cultured under  $T_{reg}$  polarising conditions in the presence of IL-2 (10 ng/ml) and TGF $\beta$  (5 ng/ml). At day 4 and 5 cells were harvested and stained for CD25 and intracellular FoxP3 and the percentage of FoxP3 $^{+}CD25^{hi}$   $T_{regs}$  were determined by flow cytometry. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments.

***Supplementary figure 3. Histological assessment of liver, lung, kidney and knee-joints. a)***


Liver, lung and kidneys from 5 week old female prediabetic  $Ptpn2^{fl/fl}$ .NOD and  $Lck-Cre;Ptpn2^{fl/fl}$ .NOD mice were fixed in formalin and processed for histological assessment (hematoxylin and eosin: H&E). **b)** Knee joints from 5 week old female prediabetic  $Ptpn2^{fl/fl}$ .NOD and  $Lck-Cre;Ptpn2^{fl/fl}$ .NOD mice fixed in formalin and decalcified in formic acid. Parasagittal serial sections were processed for histological assessment (H&E, fast green and safranin O). Joint histopathology in  $Lck-Cre;Ptpn2^{fl/fl}$  and  $Ptpn2^{fl/fl}$  mice was compared to C57Bl/6 mice with antigen-induced arthritis (AIA).

***Supplementary figure 4. Colon resident intraepithelial and lamina propria  $\gamma\delta$ -T cells in  $Lck-Cre;Ptpn2^{fl/fl}$ .NOD mice. a)***


***FACS-purified naïve  $CD4^{+}CD44^{lo}CD62L^{hi}CD25^{lo}$  lymph node T cells from  $Ptpn2^{fl/fl}$  and  $Lck-Cre;Ptpn2^{fl/fl}$  mice were cultured under  $T_{H1}$  polarising conditions in the presence of IL-6 (50 ng/ml) and TGF $\beta$  (1 ng/ml). At day 4 cells were harvested and stained for intracellular IL-17A and the percentage of IL-17A $^{+}$   $T_{H17}$  cells was determined by flow cytometry. b)*** Lymphocytes from were isolated from the colon of 5 week old female prediabetic  $Ptpn2^{fl/fl}$ .NOD and  $Lck-Cre;Ptpn2^{fl/fl}$ .NOD mice and intraepithelial versus lamina propria lymphocytes were stained for CD3 and TCR- $\delta$  and analysed by flow cytometry.

Representative contour-plots are shown. Quantified results are means  $\pm$  SEM for the indicated number of mice and are representative of two independent experiments.


A





B




C







**A**



**B**



**A***In vitro* generated T<sub>H17</sub>**B**